We are committed to serving the best interests of our shareholders.

Filter Releases
 
Press Releases
Date Title and Summary View
11/01/2012 WALTHAM, Mass., Nov. 1, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that the first clinical trial of its proprietary Anaplastic Lymphoma Kinase (ALK) inhibitor, TSR-011, has commenced with the dosing of the first patient at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Sc...
10/25/2012 Continued Enrollment for the Global Registration Program for RolapitantAnnounced Clearance of Investigational New Drug Application for TSR-011Appointed Robert E. Martell, M.D., Ph.D., as Chief Medical Officer WALTHAM, Mass., Oct. 25, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today report...
10/16/2012 WALTHAM, Mass., Oct. 16, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its third quarter 2012 financial results on Thursday, October 25th, 2012, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast on Thursday, October 25th, 2012, at 4:30 p.m. ET to discuss ...
10/02/2012 WALTHAM, Mass., Oct. 2, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that the Investigational New Drug (IND) application for TSR-011, an orally available ALK inhibitor (targeted anti-cancer agent) has become effective. The Company plans to dose the first patient in a Phase 1/2 clinical study within the next few months.  F...
9/04/2012 WALTHAM, Mass., Sept. 4, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) today announced the appointment of Dr. Robert Martell as Chief Medical Officer. Dr. Martell is a practicing medical oncologist at Tufts Medical Center who brings extensive drug development experience to TESARO from both industry and academia. He most recently served as Ass...
9/04/2012 WALTHAM, Mass., Sept. 4, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President and Chief Scientific Officer, will present at the 2012 Morgan Stanley Global Healthcare Conference at the Grand Hyatt in New York on Monday, September 10, 2012 at 3:00 p.m...
8/29/2012 WALTHAM, Mass., Aug. 29, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) today announced that Lonnie Moulder, Chief Executive Officer, will be presenting at the Robert W. Baird 2012 Healthcare Conference at the New York Palace Hotel in New York on Thursday, September 6, 2012 at 2:00 p.m. EDT. Also, the Company announced that Mr. Moulder will be...
7/26/2012 Key Rolapitant Clinical Trial Results Presented at ASCO and MASCC MeetingsIn-Licensed Niraparib, a Potentially First and Best-in-Class PARP InhibitorRaised Over $86.8 Million in Gross Proceeds from an Initial Public Offering WALTHAM, Mass., July 26, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) an oncology-focused biopharmaceutical compa...
7/24/2012 WALTHAM, Mass., July 24, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that the underwriters of its initial public offering have partially exercised their over-allotment option for the purchase of an additional 430,183 shares of TESARO common stock. All of such shares were sold by TESARO at the initial public offering price of...
7/19/2012 WALTHAM, Mass., July 19, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its second quarter 2012 financial results on Thursday, July 26th, 2012, before the open of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast on Thursday, July 26th, at 8:30 a.m. ET to discuss the Company...
= add release to Briefcase